Zydus Gets First Canada Nod for Drug

  Published 11 months ago

Zydus received its first NOC from Health Canada for ZDS-Varenicline, aiding smoking cessation, with production in Ahmedabad.

  • ZDS-Varenicline (0.5 & 1 mg) targets smoking addiction by partially activating nicotinic acetylcholine receptors in the brain.
  • Tablets to be manufactured at Zydus Lifescience SEZ unit in Ahmedabad, marking a milestone for the group in Canada.
  • Varenicline tablets saw annual sales of CAD 15 million in Canada as of December 2024 (IQVIA MAT).
You might like these

MCX Shares Jump 4.4%, Small‑Cap Leader

AI Protects Retail: PHDCCI Insights

V-Mart Q1 Profit Soars 361% YoY

Prostar Info Systems IPO Fully Subscribed

Axiscades Soars on New Orders

India's Copper Policy Attracts Foreign Smelters

Amazon & FICO Partner for AI-Powered Decisions

News that matters the most ⚡